药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
GS-5745
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with GS-5745.
Difenoxin
Luspatercept
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Luspatercept.
Difenoxin
Aducanumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Aducanumab.
Difenoxin
Ascrinvacumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ascrinvacumab.
Difenoxin
Cixutumumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Cixutumumab.
Difenoxin
Inclacumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Inclacumab.
Difenoxin
Etaracizumab
The risk or severity of adverse effects can be increased when Etaracizumab is combined with Polatuzumab vedotin.
Difenoxin
Ganitumab
The risk or severity of adverse effects can be increased when Ganitumab is combined with Polatuzumab vedotin.
Difenoxin
Zalutumumab
The risk or severity of adverse effects can be increased when Zalutumumab is combined with Polatuzumab vedotin.
Difenoxin
Etrolizumab
The risk or severity of adverse effects can be increased when Etrolizumab is combined with Polatuzumab vedotin.
Difenoxin
Tralokinumab
The risk or severity of adverse effects can be increased when Tralokinumab is combined with Polatuzumab vedotin.
Difenoxin
Dupilumab
The risk or severity of adverse effects can be increased when Dupilumab is combined with Polatuzumab vedotin.
Difenoxin
Fasinumab
The risk or severity of adverse effects can be increased when Fasinumab is combined with Polatuzumab vedotin.
Difenoxin
Simtuzumab
The risk or severity of adverse effects can be increased when Simtuzumab is combined with Polatuzumab vedotin.
Difenoxin
Duligotuzumab
The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Polatuzumab vedotin.
Difenoxin
Gevokizumab
The risk or severity of adverse effects can be increased when Gevokizumab is combined with Polatuzumab vedotin.
Difenoxin
Sotatercept
The risk or severity of adverse effects can be increased when Sotatercept is combined with Polatuzumab vedotin.
Difenoxin
Tarextumab
The risk or severity of adverse effects can be increased when Tarextumab is combined with Polatuzumab vedotin.
Difenoxin
Fulranumab
The risk or severity of adverse effects can be increased when Fulranumab is combined with Polatuzumab vedotin.
Difenoxin
Patritumab
The risk or severity of adverse effects can be increased when Patritumab is combined with Polatuzumab vedotin.